User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Tumour antigens recognised by T lymphocytes

Primary tabs

Pang, Ken C. [The Walter and Eliza Hall Institute of Medical Research] Van den Eynde, Benoît [UCL] van der Bruggen, Pierre [UCL] Chen, Weisan [La Trobe University]

Cancer cells bear markers (antigens) that identify them to the immune system. These antigens can be recognised by either cytotoxic or helper T lymphocytes, which can in turn produce a variety of anticancer effects, including direct lysis of tumour cells or indirect inhibition of tumour growth via the release of cytokines. Over the past two decades, the identity and structure of many different tumour antigens has been revealed via a range of different techniques. Some of these antigens are found only on tumour cells, whereas others can be found on both normal and cancerous tissues. Extensive efforts are currently underway to exploit this knowledge to develop effective therapeutic vaccines that elicit the immune system to eradicate cancer cells from the body.

Document type Contribution à ouvrage collectif (Book Chapter)
Publication date 2013
Language Anglais
Host document "eLS 2013"
Publisher John Wiley & Sons Ltd (Chichester)
Publication status Publié
Affiliation UCL - SSS/DDUV - Institut de Duve
Links
  1. Boon Thierry, Cerottini Jean-Charles, Van den Eynde Benoit, van der Bruggen Pierre, Van Pel Aline, Tumor Antigens Recognized by T Lymphocytes, 10.1146/annurev.iy.12.040194.002005
  2. Bronte Vincenzo, Zanovello Paola, Regulation of immune responses by L-arginine metabolism, 10.1038/nri1668
  3. Corthay Alexandre, Skovseth Dag K., Lundin Katrin U., Røsjø Egil, Omholt Hilde, Hofgaard Peter O., Haraldsen Guttorm, Bogen Bjarne, Primary Antitumor Immune Response Mediated by CD4+ T Cells, 10.1016/j.immuni.2005.02.003
  4. Davis I. D., Chen W., Jackson H., Parente P., Shackleton M., Hopkins W., Chen Q., Dimopoulos N., Luke T., Murphy R., Scott A. M., Maraskovsky E., McArthur G., MacGregor D., Sturrock S., Tai T. Y., Green S., Cuthbertson A., Maher D., Miloradovic L., Mitchell S. V., Ritter G., Jungbluth A. A., Chen Y.-T., Gnjatic S., Hoffman E. W., Old L. J., Cebon J. S., Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans, 10.1073/pnas.0403572101
  5. De Plaen Etienne, Lurquin Christophe, Lethé Bernard, van der Bruggen Pierre, Brichard Vincent, Renauld Jean-Christophe, Coulie Pierre, Van Pel Aline, Boon Thierry, Identification of Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes, 10.1006/meth.1997.0462
  6. Demotte Nathalie, Stroobant Vincent, Courtoy Pierre J., Van Der Smissen Patrick, Colau Didier, Luescher Immanuel F., Hivroz Claire, Nicaise Julie, Squifflet Jean-Luc, Mourad Michel, Godelaine Danièle, Boon Thierry, van der Bruggen Pierre, Restoring the Association of the T Cell Receptor with CD8 Reverses Anergy in Human Tumor-Infiltrating Lymphocytes, 10.1016/j.immuni.2008.01.011
  7. Dudley M. E., Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes, 10.1126/science.1076514
  8. Figdor Carl G, de Vries I Jolanda M, Lesterhuis W Joost, Melief Cornelis J M, Dendritic cell immunotherapy: mapping the way, 10.1038/nm1039
  9. Frazer Ian H., Prevention of cervical cancer through papillomavirus vaccination, 10.1038/nri1260
  10. Hodi F. Stephen, O'Day Steven J., McDermott David F., Weber Robert W., Sosman Jeffrey A., Haanen John B., Gonzalez Rene, Robert Caroline, Schadendorf Dirk, Hassel Jessica C., Akerley Wallace, van den Eertwegh Alfons J.M., Lutzky Jose, Lorigan Paul, Vaubel Julia M., Linette Gerald P., Hogg David, Ottensmeier Christian H., Lebbé Celeste, Peschel Christian, Quirt Ian, Clark Joseph I., Wolchok Jedd D., Weber Jeffrey S., Tian Jason, Yellin Michael J., Nichol Geoffrey M., Hoos Axel, Urba Walter J., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, 10.1056/nejmoa1003466
  11. Hunder Naomi N., Wallen Herschel, Cao Jianhong, Hendricks Deborah W., Reilly John Z., Rodmyre Rebecca, Jungbluth Achim, Gnjatic Sacha, Thompson John A., Yee Cassian, Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1, 10.1056/nejmoa0800251
  12. Kochenderfer J. N., Dudley M. E., Feldman S. A., Wilson W. H., Spaner D. E., Maric I., Stetler-Stevenson M., Phan G. Q., Hughes M. S., Sherry R. M., Yang J. C., Kammula U. S., Devillier L., Carpenter R., Nathan D.-A. N., Morgan R. A., Laurencot C., Rosenberg S. A., B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, 10.1182/blood-2011-10-384388
  13. Muranski P., Boni A., Antony P. A., Cassard L., Irvine K. R., Kaiser A., Paulos C. M., Palmer D. C., Touloukian C. E., Ptak K., Gattinoni L., Wrzesinski C., Hinrichs C. S., Kerstann K. W., Feigenbaum L., Chan C.-C., Restifo N. P., Tumor-specific Th17-polarized cells eradicate large established melanoma, 10.1182/blood-2007-11-120998
  14. Old Lloyd J., Chen Yao-Tseng, New Paths in Human Cancer Serology, 10.1084/jem.187.8.1163
  15. Pashine Achal, Valiante Nicholas M, Ulmer Jeffrey B, Targeting the innate immune response with improved vaccine adjuvants, 10.1038/nm1210
  16. Quezada Sergio A., Simpson Tyler R., Peggs Karl S., Merghoub Taha, Vider Jelena, Fan Xiaozhou, Blasberg Ronald, Yagita Hideo, Muranski Pawel, Antony Paul A., Restifo Nicholas P., Allison James P., Tumor-reactive CD4+T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts, 10.1084/jem.20091918
  17. Restifo Nicholas P., Dudley Mark E., Rosenberg Steven A., Adoptive immunotherapy for cancer: harnessing the T cell response, 10.1038/nri3191
  18. Rosenberg Steven A, Yang James C, Restifo Nicholas P, Cancer immunotherapy: moving beyond current vaccines, 10.1038/nm1100
  19. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., Stenner F., Luo G., Schobert I., Pfreundschuh M., Human neoplasms elicit multiple specific immune responses in the autologous host., 10.1073/pnas.92.25.11810
  20. Simpson Andrew J. G., Caballero Otavia L., Jungbluth Achim, Chen Yao-Tseng, Old Lloyd J., Cancer/testis antigens, gametogenesis and cancer, 10.1038/nrc1669
  21. Spiotto Michael T, Rowley Donald A, Schreiber Hans, Bystander elimination of antigen loss variants in established tumors, 10.1038/nm999
  22. Topalian Suzanne L., Hodi F. Stephen, Brahmer Julie R., Gettinger Scott N., Smith David C., McDermott David F., Powderly John D., Carvajal Richard D., Sosman Jeffrey A., Atkins Michael B., Leming Philip D., Spigel David R., Antonia Scott J., Horn Leora, Drake Charles G., Pardoll Drew M., Chen Lieping, Sharfman William H., Anders Robert A., Taube Janis M., McMiller Tracee L., Xu Haiying, Korman Alan J., Jure-Kunkel Maria, Agrawal Shruti, McDonald Daniel, Kollia Georgia D., Gupta Ashok, Wigginton Jon M., Sznol Mario, Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer, 10.1056/nejmoa1200690
  23. Uyttenhove Catherine, Pilotte Luc, Théate Ivan, Stroobant Vincent, Colau Didier, Parmentier Nicolas, Boon Thierry, Van den Eynde Benoît J, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase, 10.1038/nm934
  24. Van den Eynde Benoît J, van der Bruggen Pierre, T cell defined tumor antigens, 10.1016/s0952-7915(97)80050-7
  25. Villa Luisa L, Costa Ronaldo LR, Petta Carlos A, Andrade Rosires P, Ault Kevin A, Giuliano Anna R, Wheeler Cosette M, Koutsky Laura A, Malm Christian, Lehtinen Matti, Skjeldestad Finn Egil, Olsson Sven-Eric, Steinwall Margareta, Brown Darron R, Kurman Robert J, Ronnett Brigitte M, Stoler Mark H, Ferenczy Alex, Harper Diane M, Tamms Gretchen M, Yu Jimmy, Lupinacci Lisa, Railkar Radha, Taddeo Frank J, Jansen Kathrin U, Esser Mark T, Sings Heather L, Saah Alfred J, Barr Eliav, Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial, 10.1016/s1470-2045(05)70101-7
  26. Yu Ping, Rowley Donald A, Fu Yang-Xin, Schreiber Hans, The role of stroma in immune recognition and destruction of well-established solid tumors, 10.1016/j.coi.2006.01.004
  27. Zou Weiping, Regulatory T cells, tumour immunity and immunotherapy, 10.1038/nri1806
  28. Blankenstein Thomas, Coulie Pierre G., Gilboa Eli, Jaffee Elizabeth M., The determinants of tumour immunogenicity, 10.1038/nrc3246
  29. Boon Thierry, Coulie Pierre G., Eynde Benoît J. Van den, Bruggen Pierre van der, HUMAN T CELL RESPONSES AGAINST MELANOMA, 10.1146/annurev.immunol.24.021605.090733
  30. Gilboa Eli, Opinion: The promise of cancer vaccines, 10.1038/nrc1359
  31. Kirkwood John M., Butterfield Lisa H., Tarhini Ahmad A., Zarour Hassane, Kalinski Pawel, Ferrone Soldano, Immunotherapy of cancer in 2012, 10.3322/caac.20132
  32. Park Tristen S., Rosenberg Steven A., Morgan Richard A., Treating cancer with genetically engineered T cells, 10.1016/j.tibtech.2011.04.009
  33. Scott Andrew M., Wolchok Jedd D., Old Lloyd J., Antibody therapy of cancer, 10.1038/nrc3236
  34. TANTIGEN: Tumor T cell Antigen Database http://cvc.dfci.harvard.edu
  35. Vigneron Nathalie, Van den Eynde Benoît J, Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity, 10.1016/j.coi.2011.12.002
  36. Zou Weiping, Immunosuppressive networks in the tumour environment and their therapeutic relevance, 10.1038/nrc1586
Bibliographic reference Pang, Ken C. ; Van den Eynde, Benoît ; van der Bruggen, Pierre ; Chen, Weisan. Tumour antigens recognised by T lymphocytes. In: eLS 2013, John Wiley & Sons Ltd  : Chichester 2013
Permanent URL http://hdl.handle.net/2078.1/139933